Deal Watch: Immuno-Oncology Double-Header At Bristol With Rigel, Flexus Deals
• By Lisa LaMotta, Sten Stovall, Deanna Kamienski, and Amanda Micklus
Valeant jumps back into M&A, acquiring Salix after wholesale inventory issues discouraged other potential buyers. Merck more or less options a pipeline with its five-year R&D collaboration with NGM Pharma.
“The Pink Sheet” regularly provides coverage of noteworthy biopharmaceutical business deals. Here is a roundup of the most significant deals that occurred between Feb. 20-26.
Bristol-Myers Squibb Co. announced a pair of cancer immunotherapy deals on Feb. 23, inking an R&D collaboration with
